Regulatory agencies, including the FDA and EMA, are offering structured frameworks to support digital biomarker validation and integration into clinical trials. This evolving landscape is encouraging pharmaceutical and medtech companies to invest in digital endpoints, aiming to accelerate drug development timelines and enable patient-centric care models.

Major Players Analysis Listed in the Digital Biomarkers Market Report are

• Apple Inc.
• Alphabet Inc. (Google Fit, Verily)
• Microsoft Corporation
• Samsung Electronics Co., Ltd.
• Fitbit (Google)
• Garmin Ltd.
• Medtronic plc
• Abbott Laboratories
• Koninklijke Philips N.V.
• ResMed Inc.
• AliveCor, Inc.
• Oura Health Ltd.
• Withings SA
• Biofourmis Inc.
• Evidation Health, Inc.
• Neurotrack Technologies, Inc.
• Empatica Inc.
• Owlet Baby Care Inc.
• Koneksa Health, Inc.
• Elekta AB

Segment Insights

By Deployment Mode

Cloud-based solutions held the largest market share, accounting for 46.11% of the IoT in Retail market in 2025E, driven by the widespread shift of retailers toward scalable, cost-efficient, and real-time analytics platforms. Meanwhile, Hybrid solutions, expected to grow at the highest CAGR of 20.75%, as retailers seek the combined advantages of cloud flexibility and on-premise data security, ensuring optimized performance in multi-store operations.

By Biomarker Type

Physiological biomarkers dominated the market with a 38.45% share in 2025E, owing to their reliability in tracking vital parameters such as heart rate, blood glucose, and oxygen levels across wearables and connected devices. In contrast, Cognitive biomarkers are projected to expand at the highest CAGR of 21.67%, propelled by growing use of AI and digital tools to evaluate neurological and mental health conditions.

By Application

Neurology applications accounted for 32.28% of the market in 2025E, driven by the adoption of IoT-enabled systems for continuous monitoring of neurological disorders, such as Alzheimer's, Parkinson's, and epilepsy. Meanwhile, Oncology is anticipated to witness a strong CAGR of 20.34%, fueled by the integration of IoT in early cancer detection, treatment adherence tracking, and personalized therapy management, enabling real-time data collection and improved patient outcomes.

By Platform

Wearables held the dominant position with 41.52% of the market share in 2025E, due to the rapid adoption of smartwatches, biosensors, and connected patches has made them the preferred IoT interface for data-driven healthcare. On the other hand, Mobile Apps are expected to record the fastest CAGR of 22.89%, driven by rising smartphone penetration, integration of AI-powered analytics, and the convenience of app-based platforms offering personalized health insights, dietary guidance, and telehealth connectivity.

By End-User

Pharmaceutical & Biopharma companies dominated the market with 36.94% share in 2025E, leveraging IoT technologies to streamline clinical trials, monitor patient adherence, and enhance real-world data collection. Additionally, this segment is forecast to grow at a CAGR of 19.82%, supported by increasing investment in digital R&D and the expanding role of IoT in precision medicine and remote patient monitoring initiatives.

By Distribution Channel

Direct Sales accounted for 44.27% of the market in 2025E, reflecting the preference of enterprise buyers for customized IoT solutions, robust after-sales support, and secure data integration. Online Platforms are projected to grow at the fastest CAGR of 23.56%, driven by the rise of digital procurement, e-marketplaces, and subscription-based IoT platforms that provide cost transparency and simplified access to innovative retail technologies.